Malarial Drug Delivery Systems: Advances in Treatment of Infectious Diseases

ISBN-13: 9783031165061 / Angielski

Ranjita Shegokar; Yashwant Pathak

Spis treści

1 Global health and Malaria past, present and Future 2 Malaria: cellular understanding of disease 3 Drug resistance and statistics and patent status 4 Malaria: current treatment options 5 Polymeric nanoparticles in Malaria 6 Solid lipid nanoparticles in Malaria 7 Dendrimers in Malaria 8 Liposomes in Malaria 9 Micro, nano emulsions in Malaria 10 Nano suspension in Malaria 11 Alginate, gelatin nanoparticles in Malaria 12 Niosome in Malaria 13 Surface modified drug delivery systems in Malaria 14 Clinical trials in Malaria 15 Herbal platforms in Malaria 16 Exploration on Metal nanoparticles for treatment of Malaria

O autorze

Dr. Ranjita Shegokar holds a Ph.D. degree in Pharmaceutical Technology from the SNDT University, India, and has been a postdoctoral researcher in the Department of Pharmaceutics, Biopharmaceutics and NutriCosmetics at the Free University of Berlin, Germany. Since last several years she is working with various multinational pharmaceutical companies at technical/R&D leadership roles. Currently, she serves as a Chief Scientific Officer, CapnoPharm GmbH, Germany. She has authored several research articles, book chapters, and presented her research in many national/international conferences. She has filed multiple patent applications in the area of drug delivery and active targeting. Besides that, she edited many trending books on nanoparticles and their aspects. For her research, she received many prestigious national and international awards, among them the recent one is German Innovation Award 2022. Her areas of interest include polymeric nanoparticles, nanocrystals, lipid nanoparticles (SLNs/NLCs), nanoemulsions for targeting various diseases and the role of excipients in developing the same.



Dr. Yashwant Pathak completed his Ph.D. in Pharmaceutical Technology from India and EMBA and MS Conflict Management from Sullivan University, USA. He is Associate Dean for Faculty Affairs College of Pharmacy, University of South Florida. Tampa, Florida. With extensive experience in academia and industry, he has over 150 research publications, abstracts, chapters and reviews, 7 books in Nanotechnology and drug delivery systems, 6 in Nutraceuticals and several books in cultural studies. His areas of research include drug delivery systems, nanotechnology applications for pharmaceutical and Nutraceuticals. He has traveled extensively over 80 countries to network scientific experts and is actively involved with many Pharmacy colleges in different countries.

Blurb

The disability-adjusted life year (DALY) is a generic measure of health effect that can be used in cost-effectiveness analysis as an alternative to the quality-adjusted life year (QALY). Infectious diseases are one of the major to cause of significant losses of DALY and QALY. Human infectious diseases are disorders that are triggered by the micro-organisms such as bacteria, fungi, viruses, or parasites. The majority of such diseases are contagious and create a public health menace. There are several reasons why infectious diseases are deadly diseases, and one of the primary reasons is the drug resistance developed over time. Drug resistance-associated mutations are linked to increasing drug efflux, modifications of the drugs, or their targets. Every year, new drugs are being approved by FDA to treat infectious diseases. Nonetheless, infectious diseases will undoubtedly persist as permanent and main threats to humanity now and in the future, primarily due to increased longevity that almost always comes at the cost of impaired immunity.

A total of four books are covered under the series of Infectious drug diseases.

- Malarial drug delivery systems

- Tubercular drug delivery systems

- Viral drug delivery systems

- Infectious disease drug delivery systems

The theme of the first book is Malaria. This book compiles the complete road map of malarial drug delivery systems by understanding the pathophysiology of the disease, the current state of malaria across the world, new clinical trials, emerging drugs, and the development of novel drug delivery platforms. Various novel micro-and nano-formulations using promising technologies are being explored to deliver the malarial drug via different administration routes. This book addresses the gap between new approaches and old treatment modalities and how the former is superior in pharmacological performance when tested in in-vitro and in-vivo.

Audiences from a broad range of groups, from researchers, academicians, and public health bodies to regulatory experts, can benefit from the compiled information to learn more about patient needs and current research advances in the field of malarial research